Optimisation of Ondansetron Orally Disintegrating Tablets Using Artificial Neural Networks

被引:14
|
作者
Aksu, Buket [1 ]
Yegen, Gizem [2 ]
Purisa, Sevim [3 ]
Cevher, Erdal [2 ]
Ozsoy, Yildiz [2 ]
机构
[1] Santa Farma Drug Pharmaceut, Sisli, Turkey
[2] Istanbul Univ, Fac Pharm, Dept Pharmaceut Technol, Istanbul, Turkey
[3] Istanbul Univ, Fac Med, Dept Biostat, Istanbul, Turkey
关键词
Ondansetron; Critical quality attributes; Critical process parameters; Quality target product profile; Gene expression programming; Neuro-fuzzy logic; Artificial neural network; INTELLIGENCE TECHNIQUES; NEUROFUZZY LOGIC; DESIGN; GRANULATION; FORMULATION; KNOWLEDGE; QUALITY;
D O I
10.4314/tjpr.v13i9.1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the impact of critical quality attributes (CQAs) and critical process parameters (CPPs) on quality target product profile (QTPP) attributes of orally disintegrating tablet (ODT) containing ondansetron (OND) using two artificial neural network (ANN) programs. Methods: Different amounts of two different commercial superdisintegrants commonly used in ODT formulations (Ludiflash (R) and Parteck (R)) were examined as CQAs, while three different tablet-pressing forces were evaluated as CPPs for an orally disintegrating tablet (ODT) formulation. The impact of CQAs, and CPPs on the target product profile (tablet hardness, friability and disintegration time) were analysed using gene expression programming (GEP) and neuro-fuzzy logic (NFL) models. Results: NFL model defined the relations between CQAs, CPPs and QTPP, while GEP model favoured the use of an ODT formulation with suitable QTPP features which contained 4 mg ondansetron, 21.30 mg Parteck (R), and 119 mg Avicel, fabricated with a compression force of 515 psi. In this regard, the tablet formulation demonstrated the required specifications. Conclusion: ANN programs are a useful tool for research and development (R&D) studies in the pharmaceutical industry and the use of ANNs can be beneficial in terms of raw materials, time and cost, as demonstrated for ondansetron ODT tablets.
引用
收藏
页码:1379 / U22
页数:10
相关论文
共 50 条
  • [1] Formulation and In Vivo Evaluation of Ondansetron Orally Disintegrating Tablets Using Different Superdisintegrants
    Sheshala, Ravi
    Khan, Nurzalina
    Chitneni, Mallikarjun
    Darwis, Yusrida
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (11) : 1945 - 1956
  • [2] Formulation and in vivo evaluation of ondansetron orally disintegrating tablets using different superdisintegrants
    Ravi Sheshala
    Nurzalina Khan
    Mallikarjun Chitneni
    Yusrida Darwis
    Archives of Pharmacal Research, 2011, 34 : 1945 - 1956
  • [3] DESIGN AND DEVELOPMENT OF ONDANSETRON ORALLY DISINTEGRATING TABLETS AND ITS OPTIMIZATION USING DESIGN OF EXPERIMENT
    Bhasin, Rakesh Kumar
    Ghosh, Pradip Kumar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2012, 3 (03): : 840 - 847
  • [4] Orally disintegrating tablets using starch and fructose
    Morales, Javier O.
    Horng, Michelle
    Gregg, Aubrey M.
    McConville, Jason T.
    Pharmaceutical Technology, 2010, 34 (11) : 92 - 99
  • [5] EFFECT OF SELECTED EXCIPIENTS AND THE PREPARATION METHOD ON THE PARAMETERS OF ORALLY DISINTEGRATING TABLETS CONTAINING ONDANSETRON
    Siemiradzka, Wioletta
    Szulc-Musiol, Beata
    Bulas, Lucyna
    Jankowski, Andrzej
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (03): : 733 - 740
  • [6] Orally Disintegrating Tablets: A Review
    Hirani, Jaysukh J.
    Rathod, Dhaval A.
    Vadalia, Kantilal R.
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2009, 8 (02) : 161 - 172
  • [7] Orally disintegrating tablets and orally disintegrating mini tablets - novel dosage forms for pediatric use
    Comoglu, Tansel
    Ozyilmaz, Emine Dilek
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2019, 24 (07) : 902 - 914
  • [8] DEVELOPMENT OF ORALLY DISINTEGRATING FIXED DOSE COMBINATION TABLETS CONTAINING ONDANSETRON HYDROCHLORIDE AND DEXKETOPROFEN TROMETAMOL
    Ugurlu, Timucin
    Abay, Fikriye Bilgehan
    ACTA POLONIAE PHARMACEUTICA, 2017, 74 (04): : 1203 - 1214
  • [10] Comparison of superdisintegrants in orally disintegrating tablets
    Zhang, Yeli
    Wrzesinski, Amy
    Moses, Marley
    Bertrand, Holly
    Pharmaceutical Technology, 2010, 34 (07) : 54 - 61